European myocardial infarction (MI) market is estimated to grow modestly, at a CAGR of around 6.2%, during the forecast period. Rising heart patients, cohesive European healthcare policies, rising adoption of minimally invasive/non-invasive surgeries, and technological advancement in MI treatment is boosting the European MI treatment market. The European drug market is predicted to contribute highest in the growth of the MI treatment market followed by the device market due to the huge adoption of cardiology drugs, high cost of drugs, and favorable government policies. Europe region which includes UK, Spain, Germany, France, Italy, Sweden, and other EU countries have a significant number of CVD patients with heart diseases which are giving rise to the adoption of robotic surgeries and hybrid operating rooms.

Eastern Europe has the highest rates for CVD, CHD, and other heart diseases which create huge demand for cardiology related surgeries in the region. Europe has a quality healthcare system; however, the surgeries and medical devices are costly. In Europe, in April 2019, Britain's heart Foundation has launched a global competition namely “The Big Bit Challenge” with the prize amounting to $39 million to propose a transformational solution to any CVD disease. Europe has a huge economic burden of lifestyle-oriented diseases such as CVD, CHD, MI treatment, stroke, and other heart diseases.

The market is segmented into type, device, diagnosis, treatment, and end-user. Based on type, the market is segmented into ST-elevation myocardial infarction (STEMI) heart attacks, non-ST elevation myocardial infarction (NSTEMI) heart attacks, and silent heart attacks. Based on the device, the market is segmented into left ventricular assist device, pacemaker, implantable cardioverter defibrillator, and others (aspiration-based catheters). Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest X-Ray, Computed Tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics, Ambulatory Surgical Centers (ASCs), and research institutes.

The companies which are contributing to the growth of the European myocardial infarction market include AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Novartis AG, GlaxoSmithKline PLC, Koninklijke Philips N.V., Medtronic PLC, Merck KGaA, and Sanofi SA. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market. For instance, in January 2020, Novartis AG acquired the Medicines Company which is in aims to reduce cardiovascular disease patients by providing LDL cholesterol to the people suffering from atherosclerotic cardiovascular. This acquisition will enable the company to leverage its customers with an advanced treatment option.

Research Methodology

The market study of the European myocardial infarction market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.

Market Segmentation

1. European Myocardial Infarction Market Research and Analysis by Type
2. European Myocardial Infarction Market Research and Analysis by Device
3. European Myocardial Infarction Market Research and Analysis by Diagnosis
4. European Myocardial Infarction Market Research and Analysis by Treatment
5. European Myocardial Infarction Market Research and Analysis by End-Users

The Report Covers

• Comprehensive research methodology of the European myocardial infarction market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the European myocardial infarction market.
• Insights about market determinants which are stimulating the European myocardial infarction market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.